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Reason for Erratum:
Due to a typesetting error, the article was published with incorrect values in Table 4 . The publisher
apologizes for this error and the correct version of Table 4 appears below. This error does not
change the scientific conclusions of the article in any way.
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TABLE 4 | MM-PBSA results compared to experimental binding parameters.
Complex Binding parameters MM-PBSA energy terms (KJ/mol)
Kon/105 (M−1 s−1) Koff/10
−5 (s−1) KD (pM) 1Ebinding 1EVdW 1Eelectrostatic 1GPolar 1GApolar
Ranibizumab/VEGFA 1.60 0.73 46 −760 ± 40 −418 ± 5 −160 ± 20 410 ± 30 −592 ± 7
Fab-bevacizumab/VEGFA 5.30 3.10 58 −807 ± 30 −362 ± 10 −252 ± 20 343 ± 30 −536 ± 7
VEGFR1d2_R2d3/VEGFA 410 2.01 0.49 −1440 ± 90 −307 ± 50 −1433 ± 100 1050 ± 100 −750 ± 40
Kinetic and binding parameters are from Papadopoulos et al. (2012).
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